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COMMENT OPEN
Social license for the use of big data in the COVID-19 era
James A. Shaw 1,2✉, Nayha Sethi3 and Christine K. Cassel4
Strategies to enable the reopening of businesses and schools in countries emerging from social-distancing measures revolve
around knowledge of who has COVID-19 or is displaying recognized symptoms, the people with whom they have had physical
contact, and which groups are most likely to experience adverse outcomes. Efforts to clarify these issues are drawing on the
collection and use of large datasets about peoples’ movements and their health. In this Comment, we outline the importance of
earning social license for public approval of big data initiatives, and specify principles of data law and data governance practices
that can promote social license. We provide illustrative examples from the United States, Canada, and the United Kingdom.
npj Digital Medicine           (2020) 3:128 ; https://doi.org/10.1038/s41746-020-00342-y
Understanding the transmission, prevalence, and clinical char-
acteristics of COVID-19 is essential for relaxing social distancing,
shelter-in-place, and other policies carrying significant detrimental
effects on national economies. Many countries are finding ways to
expand large datasets that, with the support of advanced analytics
and artificial intelligence, promise to answer crucial questions
about the disease and its spread1. These initiatives raise
challenges related to ethics, governance, and public attitudes. If
these challenges are not addressed in ways that are transparent
and broadly satisfying to the public, they risk public criticism, loss
of public trust, and potentially premature shut down2.
We define the concept of social license and describe its
relevance for health-related big data initiatives such as those
proposed to mitigate the spread of COVID-19. We propose trust-
enhancing governance practices that can increase trustworthiness
in data gathering for public health purposes, drawing on
experience in Canada, the United Kingdom and the United States.
SOCIAL LICENSE MATTERS FOR BIG DATA INITIATIVES
Although every data initiative must give due regard to privacy and
security requirements as prescribed within legislation, an equally
important yet distinct set of concerns relates to social license of
data uses. Here, we focus on the latter, arguing that it is
particularly important given the reliance on public uptake of
contact tracing apps and similar technologies to be effective as
public health interventions.
Social license refers to the informal permissions granted to
institutions such as governments or corporations by members of
the public to carry out a particular set of activities3,4. Much of the
literature on the topic of social license has arisen in the field of
natural resources management, emphasizing issues that include
but go beyond environmental stewardship4. In their seminal work
on social license in the pulp and paper industry, Gunningham
et al. defined social license as the “demands and expectations”
placed on organizations by members of civil society which “may
be tougher than those imposed by regulation”; these expectations
thereby demand actions that go beyond existing legal rules to
demonstrate concern for the interests of publics5. We use the
plural term “publics” as opposed to the singular “public” to
illustrate that stakeholder groups to which organizations must
appeal are often diverse and varied in their assessments of
whether a given organizational activity is acceptable6. Despite the
potentially fragmented views of various publics, the concept of
social license is considered in a holistic way (either an organization
has it or does not). Social license is closely related to public trust,
and where publics view a particular institution as trustworthy it is
more likely to have social license to engage in activities such as
the collection and use of personal data7.
The question of how the leaders of an organization might better
understand whether they have social license for a particular set of
activities has also been addressed in the literature. In a review of
literature on social license, Moffat et al. highlighted disagreement
in the research community about whether social license can be
accurately measured4. Certain groups of researchers emphasize
that because of the intangible nature of social license, accurate
measurement will never truly be possible. Others propose
conceptual models of the determinants of social license, and
establish surveys that assess those determinants to indicate the
presence or absence of social license in a given context. However,
accurate measurement of social license remains a point of debate.
Literature on social license related to health care is sparse,
despite conflicting evidence about the extent to which publics
consider the individuals, organizations, and systems that consti-
tute health care to be trustworthy8,9. However, a small body of
literature exists related to social license and the use of personal
health information for health-related research and policymaking;3
we provide select examples in the following section. In relation to
initiatives seeking to build and leverage large datasets to better
understand the nature and spread of COVID-19, certain govern-
ance strategies are more likely to have a positive effect on public
trust and thereby promote the social license to enable their use.
Decisions around data use must align with the social license
granted to particular institutions to compile and use data for
public health purposes during the pandemic3.
PUBLIC TRUST IN HEALTH DATA SHARING
Many people are supportive of their health-related data being
shared to support research and public health policy when certain
conditions apply. A recent review of the literature summarized
conditions that must be met from perspectives of various
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members of the public, including that health data are used for
public benefit, in transparent ways, and by trusted institutions10.
The recent experience of “Project Nightingale”, a partnership
between Ascension Health System and Google to use advanced
analytics to gain insights into patient data, is illustrative of what
happens when transparency and trustworthiness are lacking. The
apparent secrecy of the project motivated a powerful public
backlash that ultimately led to a formal investigation by the US
Department of Health and Human Services2. Projects in the United
Kingdom have had a similar fate, such as the abandonment of the
“care.data initiative” to collate data from primary care practices
across the country as a result of resistance from health care
providers and the public3.
The experiences documented in these projects may be
contrasted with other health-related big data initiatives that have
not been deemed as problematic by publics. For example, Mayo
Clinic in Rochester, Minnesota struck a 10-year collaboration with
Google to support their digital transformation of care; Wachter
and Cassel suggested that the lack of controversy surrounding this
particular initiative was due to its transparency2. The collaboration
was made public before any data sharing occurred. Although no
process exists to specify the extent to which the Mayo Clinic-
Google collaboration enjoyed social license where the Ascension-
Google collaboration did not, the public outcry arising from
investigative journalism that revealed the latter to the public is an
important consideration. In our view, the transparent and forth-
coming nature of the announcement regarding the Mayo Clinic-
Google collaboration allowed for less distrust and related backlash
among the public.
Although conditions demonstrating transparency and trust-
worthiness can be met by certain health data analytics initiatives2,
not all communities will agree on the nature of the conditions that
must be met. One issue that requires special attention in any effort
to collect and use personal data related to the COVID-19
pandemic is the informed mistrust of health systems by particular
communities. For example, histories of structural racism and other
exclusionary practices in health care in the United States have led
to warranted suspicion and avoidance of mainstream health care
by African Americans11. Other communities have also faced biases
and systematic barriers to fair treatment in health care, including
Indigenous Peoples, those with disabilities, people living with
homelessness, and other marginalized groups. Many of these
communities are the same ones who have been disproportio-
nately affected by COVID-19, and controlling the spread of COVID-
19 requires strategies that appeal to these communities. Earning
social license to engage in activities such as digitally enabled
contact tracing therefore requires special attention to information
needs, opinions, and potential unintended consequences for
communities who bear disproportionate risk of being harmed or
perceiving risk of harm.
DATA GOVERNANCE FOR SOCIAL LICENSE IN THE COVID-19
ERA
Policy strategies to enable the reopening of businesses and
schools in countries emerging from orders of shelter-in-place and
similar social-distancing measures revolve around knowledge of
who has COVID-19, the people with whom they have had physical
contact, and which groups are most likely to experience adverse
outcomes. This information is essential to prevent additional
spikes in the number of COVID-19 cases while enabling people to
engage in a modified (i.e., socially distanced) version of everyday
activities. Three strategies involving large health related datasets
are central to these aims. First, using data about the proximity of
known COVID-19 cases to other members of the public via mobile
phones (digitally enabled contact tracing); second, forecasting
specific areas more likely to experience outbreaks; and third,
better understanding which proportions of populations are most
likely to need high resource care. These data platforms can be
used to aid in resource allocation such as ICU beds in a city during
a surge.
The ways in which the data in each of these examples are
acquired, used and governed vary considerably. For example, in
some jurisdictions the use of digital contact tracing applications is
mandatory (guaranteeing the generation of a related dataset),
whereas in others it is voluntary (relying on express consent
associated with the use of the application). Conversely, a majority
of countries have infrastructure to collect data regarding basic
characteristics of members of the public who have tested positive
for COVID-19, enabling the generation of large population-wide
datasets of known cases. Despite the variability in models of
consent and data collection across these particular initiatives, we
suggest that the links between data governance strategies and
the attainment of social license are strong in all cases.
Although data governance strategies that exemplify trust-
worthiness are not alone sufficient to earn social license, we
suggest that by demonstrating trustworthiness, good data
governance can promote the attainment of social license. We
propose that governance practices to promote trustworthiness
and thereby promote the likelihood of attaining social license in
these initiatives involve three interrelated yet distinct key features.
In what follows, we outline principles of data privacy law and the
data governance practices they recommend. The data privacy law
principles we outline are distinct from social license as a concept,
however abiding by these principles and the data governance
practices they recommend can enhance the likelihood of earning
social license in a given data initiative. We have selected these
principles of focus for their commonality across many jurisdictions
internationally and their links to the concept of social license
outlined earlier.
First, the data used ought to be only those that are essential to
achieve the specific public health goal of the initiative; this refers
to the data privacy law principle of purpose limitation. For
example, Article 5(1) of the General Data Protection Regulation
demands that data processing is “adequate, relevant and limited
to what is necessary in relation to the purposes for which they are
processed12.” Purpose limitation is similar to but different from the
related principle of data minimization, which refers to the act of
limiting the type and quantity of data collected specifically to that
which is necessary to perform the intended analysis. In the case of
initiatives to compile and use data during the pandemic, clear
statements of the uses to which data will be put can enhance the
trustworthiness of the initiative involving the analysis of the data,
thereby enhancing the likelihood of securing social license.
However, limiting the data used in the analyses outlined earlier
(digital contact tracing, forecasting outbreaks, and allocating
resources) also presents challenges. For example, excluding
particular data elements from model development can result in
a biased model that would have been more accurate and effective
if trained on a broader dataset. Strategies to address these
challenges, such as purposefully selecting and retaining those
variables that might cause bias in the model if removed, will
contribute to effective model development while maintaining the
importance of good data governance practices that promote
social license.
Second, we suggest that governance practices necessitate
transparency. Specifically publics must be kept informed on the
progress and plans of data use initiatives and ongoing decisions
made. Especially during the continually evolving effort to control
the spread of COVID-19 while reopening businesses and other
sectors of the economy, establishing strategies to regularly inform
publics on a large scale is essential. Regular updates about data
sharing and uses, organizations involved, and the input received
from public advisory bodies would bolster the effort to acquire and
maintain social license for such initiatives. Acknowledging the
challenges associated with the transparent provision of information
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to publics about conceptually difficult topics such as machine
learning, we suggest that expert input into educational strategies to
accomplish this goal would enhance the likelihood of attaining
social license for digital contact tracing, forecasting spread of
COVID-19, and informing the allocation of resources.
Finally, we suggest that sustained commitment to public
involvement is crucial. This must include but go beyond strategies
to educate the public, which are often viewed as paternalistic,
one-directional and “top-down”. Although raising awareness of
data uses is important for improving public understandings of
data use, meaningful public engagement involves two-way,
ongoing communication with publics in order to explore attitudes
towards data uses and to reflect these concerns within govern-
ance frameworks adopted13.
Precedent exists around the world for the data governance
practices we have described here. For example, the Public Benefit
and Privacy Panel in Scotland includes public representatives in
addition to other stakeholders who scrutinize applications to use
National Health Services (NHS) Scotland health data. At the
Institute of Clinical Evaluative Sciences in Ontario, Canada (a large
health data repository), a Public Advisory Council provides input
on a variety of data access and analysis initiatives. These groups
are in place to ensure that data uses are appropriate from the
perspective of the public interest, and to provide a mechanism for
public involvement in data governance. Although there has not
historically been great investment in large-scale transparency for
big data initiatives14, it is clear that promoting social license
during the pandemic will require it.
Drawing on insights from past successes and failures of data
governance around the world, governments and their partners
can ensure health data is used in ways that are legally sound and
acceptable to the public. Doing so is essential to mobilizing large
datasets in ways that contribute to the control of and response to
the COVID-19 pandemic.
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